http://www.drugs.com/clinical_trials.html Clinical trial news from Drugs.com. Comprehensive and up-to-date drug news for both consumers and healthcare professionals. en http://www.drugs.com/clinical_trials/ucla-presents-data-medicinova-s-mn-166-methamphetamine-15771.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss UCLA Presents Data on MediciNova's MN-166 in Methamphetamine Addiction at the 75th Annual Meeting of the College on Problems of Drug Dependence    Leading Addiction Researchers Discuss MN-166 in Symposium on... Wed, 19 Jun 2013 17:30:24 GMT http://www.drugs.com/clinical_trials/study-stendra-effective-sexual-activity-within-15-minutes-men-ed-15770.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss VIVUS Announces Study Results Showing STENDRA (Avanafil) is Effective for Sexual Activity Within 15 Minutes in Men With Erectile Dysfunction (ED)    Data From Successful Placebo-Controlled Study to be Submitted    to... Wed, 19 Jun 2013 16:41:35 GMT http://www.drugs.com/clinical_trials/pluristem-provides-update-clinical-status-ic-trials-15769.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss HAIFA, Israel, June 19, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, provided an update today on the status of its clinical trials in... Wed, 19 Jun 2013 16:18:42 GMT http://www.drugs.com/clinical_trials/aurigene-debiopharm-group-report-nomination-development-candidate-debio-0617b-oncology-15768.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss LAUSANNE, Switzerland and BANGALORE, India, June 19, 2013 /PRNewswire/ -- Aurigene Discovery Technologies, a Bangalore-based biotech focusing on small molecule and peptide drug discovery and Debiopharm Group™ (Debiopharm), a... Wed, 19 Jun 2013 15:51:24 GMT http://www.drugs.com/clinical_trials/neuroderm-announces-presentation-data-studies-evaluating-nd0612-15767.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease NESS ZIONA, Israel, June... Wed, 19 Jun 2013 15:50:34 GMT http://www.drugs.com/clinical_trials/nektar-therapeutics-presents-positive-data-human-abuse-liability-study-nktr-181-15766.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence NKTR-181... Wed, 19 Jun 2013 15:49:29 GMT http://www.drugs.com/clinical_trials/boehringer-ingelheim-athera-artherosclerosis-pact-15765.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss Athera and Boehringer Ingelheim enter into an option agreement on a novel therapy for Atherosclerosis STOCKHOLM, SWEDEN – June 19, 2013. Athera Biotechnologies AB today announced that it has entered into an option agreement with... Wed, 19 Jun 2013 12:34:46 GMT http://www.drugs.com/clinical_trials/astrazeneca-bms-diabetes-disappoints-heart-trial-15764.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss AstraZeneca and Bristol-Myers Squibb announce top-line results for SAVOR-TIMI-53 cardiovascular outcomes trial of ONGLYZA® (SAXAGLIPTIN) June 19, 2013 - AstraZeneca and Bristol-Myers Squibb announced today top-line results of the... Wed, 19 Jun 2013 11:06:00 GMT http://www.drugs.com/clinical_trials/astex-pharmaceuticals-announces-presentation-updated-results-sgi-110-01-study-15763.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss Astex Pharmaceuticals Announces Presentation of Updated Results of SGI-110-01 Study in Patients With Intermediate or High Risk Relapsed or Refractory Myelodysplastic Syndromes at the European Hematology Association... Tue, 18 Jun 2013 18:26:32 GMT http://www.drugs.com/clinical_trials/genmab-adc-therapeutics-enter-co-development-collaboration-antibody-conjugate-combining-humax-tac-15762.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss •    Antibody-drug conjugate (ADC) to be developed for cancer •    Combines strength of HuMax®-TAC with next generation PBD-based warhead technology •    50:50 partnership Copenhagen, Denmark and Lausanne,... Tue, 18 Jun 2013 17:49:56 GMT http://www.drugs.com/clinical_trials/kineta-rosa-strategic-alliance-next-stage-clinical-development-lead-candidate-shk-186-15761.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss SEATTLE, WA, June 14, 2013 - Kineta, Inc. a biotechnology company focused on the development of novel modulating drugs for critical disease areas, announced today a strategic alliance with Rosa & Co. LLC (www.rosaandco.com), a drug... Tue, 18 Jun 2013 17:26:49 GMT http://www.drugs.com/clinical_trials/santarus-pharming-announce-fda-acceptance-review-ruconest-15760.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss Santarus And Pharming Announce FDA Acceptance For Review Of Ruconest (Recombinant Human C1 Esterase Inhibitor) Biologics License Application SAN DIEGO & Leiden, The Netherlands (June 18, 2013) Santarus, Inc. (NASDAQ: SNTS) and... Tue, 18 Jun 2013 17:24:52 GMT http://www.drugs.com/clinical_trials/hyperion-therapeutics-announces-ravicti-buphenyl-pharmacokinetic-analyses-15759.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss Hyperion Therapeutics Announces RAVICTI and BUPHENYL Pharmacokinetic Analyses Reported in The Journal of Clinical Pharmacology SOUTH SAN FRANCISCO, Calif., June 18, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc.... Tue, 18 Jun 2013 17:18:34 GMT http://www.drugs.com/clinical_trials/phrma-joins-national-minority-quality-forum-microsoft-address-diversity-clinical-trials-15758.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss WASHINGTON, D.C. (June 18, 2013) – The Pharmaceutical Research and Manufacturers of America (PhRMA) announced today that it is partnering with the National Minority Quality Forum (NMQF) and Microsoft to help increase diversity in... Tue, 18 Jun 2013 16:51:41 GMT http://www.drugs.com/clinical_trials/forma-therapeutics-launches-new-collaborative-framework-transform-basic-research-into-promising-15757.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss ADDCos uniquely integrate FORMA’s drug discovery engine with academic-based innovators for patient benefit WATERTOWN, Mass. - June 18, 2013 – FORMA Therapeutics announced today its Asset Discovery and Development Company... Tue, 18 Jun 2013 16:50:34 GMT http://www.drugs.com/clinical_trials/nuvo-research-paladin-labs-announce-amendment-may-2012-loan-arrangement-15756.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss MISSISSAUGA, ON and MONTREAL, QC, June 17, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of... Tue, 18 Jun 2013 16:44:16 GMT http://www.drugs.com/clinical_trials/vanda-presents-data-phase-iii-studies-15755.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder Data presented at ENDO 2013, the Endocrine Society's 95th Annual Meeting... Tue, 18 Jun 2013 16:43:11 GMT http://www.drugs.com/clinical_trials/ico-therpeutics-completes-enrollment-phase-ii-study-15754.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss iCo Therapeutics Announces Completion of Trial Enrollment and Clinical Update for iDEAL Phase 2 Study for the Treatment of Diabetic Macular Edema VANCOUVER, June 18, 2013 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the... Tue, 18 Jun 2013 16:41:13 GMT http://www.drugs.com/clinical_trials/adamas-pharmaceuticals-presents-positive-phase-2-3-results-ads-510-15753.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease SYDNEY, Australia And EMERYVILLE, Calif., June 18, 2013 /PRNewswire/ -- Adamas... Tue, 18 Jun 2013 16:36:16 GMT http://www.drugs.com/clinical_trials/mei-pharma-initiates-phase-ii-clinical-trial-pracinostat-vidaza-15752.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss Mei Pharma Initiates Phase II Clinical Trial Of Pracinostat And Vidaza® In Frontline Myelodysplastic Syndrome First Patients Dosed in Multicenter, Randomized, Placebo-Controlled Study SAN DIEGO, June 18, 2013 /PRNewswire/ -- MEI... Tue, 18 Jun 2013 16:33:58 GMT http://www.drugs.com/clinical_trials/lilly-study-livalo-helps-hiv-patients-15751.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss New Data Showed Livalo (Pitavastatin) 4 Mg Had Neutral Effects on Fasting Serum Glucose and Hba1c Levels in HIV-Infected Adults With Dyslipidemia Study results presented at ENDO 2013 Annual Meeting SAN FRANCISCO, June 17, 2013... Tue, 18 Jun 2013 11:59:01 GMT http://www.drugs.com/clinical_trials/tg-therapeutics-inc-announces-clinical-pre-clinical-poster-presentations-tg-1101-tgr-1202-15750.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss TG Therapeutics, Inc. Announces Clinical and Pre-Clinical Poster Presentations for TG-1101 and TGR-1202 at the European Hematology Association (EHA) Meeting in Stockholm, Sweden NEW YORK, June 17, 2013 (GLOBE NEWSWIRE) -- TG... Mon, 17 Jun 2013 18:42:19 GMT http://www.drugs.com/clinical_trials/novabay-supports-legislation-attack-antibiotic-resistance-ceo-cites-growing-crisis-15749.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss EMERYVILLE, Calif., June 17, 2013 (GLOBE NEWSWIRE) -- Dr. Ron Najafi, Chairman and Chief Executive Officer of NovaBay Pharmaceuticals, Inc. (NYSE:NBY) today announced NovaBay's support for legislation by U.S. Rep. Jim Matheson... Mon, 17 Jun 2013 18:14:43 GMT http://www.drugs.com/clinical_trials/acetylon-pharmaceuticals-presents-encouraging-safety-clinical-response-data-ongoing-clinical-trials-15748.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss Acetylon Pharmaceuticals Presents Encouraging Safety and Clinical Response Data from Ongoing Clinical Trials of ACY-1215 for the Treatment of Multiple Myeloma -- Data Presented at the 18th Congress of the European Hematology... Mon, 17 Jun 2013 18:13:14 GMT http://www.drugs.com/clinical_trials/abbvie-presents-preliminary-results-phase-study-investigational-oncology-compound-abt-199-gdc-0199-15747.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting” June... Mon, 17 Jun 2013 18:11:30 GMT http://www.drugs.com/clinical_trials/mayo-clinic-rotavirus-vaccine-given-newborns-africa-effective-15746.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss Vaccine may save thousands of lives annually ROCHESTER, Minn., June 14, 2013  — Mayo Clinic and other researchers have shown that a vaccine given to newborns is at least 60 percent effective against rotavirus in Ghana.... Mon, 17 Jun 2013 18:10:16 GMT http://www.drugs.com/clinical_trials/act-ad-coalition-takes-action-against-alzheimer-s-15745.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss By Mia Burns Prominent figures with ties to fighting Alzheimer's disease have recently announced preliminary recommendations for a “roadmap to combination therapies for Alzheimer’s disease” at the final session of a three-day... Mon, 17 Jun 2013 13:32:23 GMT http://www.drugs.com/clinical_trials/act-ad-coalition-coordinates-action-steps-fight-alzheimer-s-15744.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss Recommendations to Develop a Roadmap to Alzheimer’s Disease Combination Therapy Issued From Meeting of Regulatory, Industry, Research and Funding Leaders   -- ACT-AD Coalition Coordinates Action Steps to Facilitate Further... Mon, 17 Jun 2013 13:30:33 GMT http://www.drugs.com/clinical_trials/gilead-s-idelalisib-shows-response-refractory-indolent-non-hodgkin-s-lymphoma-15743.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss Gilead Announces Interim Phase 2 Data for Idelalisib Showing Response in Refractory Indolent Non-Hodgkin’s Lymphoma -- 53.6 Percent Overall Response Rate and Median Duration of Response of 11.9 Months in Heavily Pre-Treated... Mon, 17 Jun 2013 13:22:00 GMT http://www.drugs.com/clinical_trials/medikly-teams-inventiv-health-faster-clinical-trials-15742.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss By Mia Burns inVentiv Health Inc. has announced a partnership with Medikly, Inc., as part of a continuous  effort to assist pharma companies in developing better drugs faster and in a more cost effective manner, and in turn,... Mon, 17 Jun 2013 13:17:20 GMT http://www.drugs.com/clinical_trials/inventiv-health-partners-medikly-speed-clinical-trials-15741.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss inVentiv Health Partners with Medikly to Speed Clinical Trials by Accelerating the Recruitment of Investigators Medikly’s Sophisticated Technology Helps to More Effectively Identify and Engage Investigators Burlington, Mass.... Mon, 17 Jun 2013 13:13:00 GMT http://www.drugs.com/clinical_trials/astrazeneca-medimmune-ngm-biopharmaceuticals-diabetes-obesity-deal-15740.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss MedImmune, AstraZeneca’s biologics arm, and NGM Biopharmaceuticals announce agreement to discover and develop therapies for diabetes and obesity LONDON, 17 June 2013 - AstraZeneca today announced that MedImmune, its global... Mon, 17 Jun 2013 12:56:43 GMT http://www.drugs.com/clinical_trials/gilead-s-idelalisib-shows-response-refractory-indolent-non-hodgkin-s-lymphoma-15739.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss Gilead Announces Interim Phase 2 Data for Idelalisib Showing Response in Refractory Indolent Non-Hodgkin’s Lymphoma -- 53.6 Percent Overall Response Rate and Median Duration of Response of 11.9 Months in Heavily Pre-Treated... Mon, 17 Jun 2013 12:51:51 GMT http://www.drugs.com/clinical_trials/lilly-assumes-rights-transition-type-2-diabetes-15738.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss Transition Therapeutics Announces Exercise of TT-401 Rights by Lilly TORONTO, June 17, 2013 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced that Eli Lilly and Company... Mon, 17 Jun 2013 12:30:44 GMT http://www.drugs.com/clinical_trials/bms-abbvie-pfs-phase-ii-elotuzumab-study-15737.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss Bristol-Myers Squibb and AbbVie Announce Progression-Free Survival Data from Phase 2 Open-Label Study of Investigational Agent Elotuzumab in Combination with Lenalidimide and Dexamethasone in Previously-Treated Multiple Myeloma... Mon, 17 Jun 2013 11:34:10 GMT http://www.drugs.com/clinical_trials/novartis-jakavi-improved-overall-survival-myelofibrosis-patients-15736.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss Novartis drug Jakavi® improved overall survival of myelofibrosis patients and impacted an underlying mechanism of disease Jakavi® reduced risk of death by 52% and sustained reductions in spleen size in new three-year COMFORT-II... Mon, 17 Jun 2013 11:15:35 GMT http://www.drugs.com/clinical_trials/lilly-ends-phase-ii-alzheimer-s-study-over-liver-problems-15735.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimer's Disease Decision does not impact other Lilly Alzheimer's compounds in development... Thu, 13 Jun 2013 21:10:15 GMT http://www.drugs.com/clinical_trials/galapagos-presents-glpg0634-eular-poster-session-15733.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss Posters now available online at www.glpg.com Q&A session with Galapagos CSO today at 15.00 CET/9 AM EDT/6 AM PT, call numbers for the teleconference call: US +1-480-629-9645, Toll-free +1-877-941-60; Belgium +32-2290-1608,... Thu, 13 Jun 2013 18:52:11 GMT http://www.drugs.com/clinical_trials/nanobiotix-receives-approval-ansm-start-new-clinical-trial-lead-product-nbtxr3-15734.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss Second indication for NanoXray product in Head and Neck cancer patients Paris, France, June 13, 2013 – NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of... Thu, 13 Jun 2013 18:06:13 GMT http://www.drugs.com/clinical_trials/anergis-files-provisional-u-s-patent-allerdm-dust-mite-allergy-15732.html?utm_source=ddc&utm_medium=rss&utm_campaign=rss Anergis Files Provisional U.S. Patent on AllerDM Dust Mite Allergy Treatment - Further expansion of the company’s product pipeline and patent estate - EPALINGES, Switzerland, June 13, 2013 – Anergis, a company focusing on... Thu, 13 Jun 2013 17:07:21 GMT